![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 37, 34509-34516, September 14, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, March 21, 2001, and in revised form, June 27, 2001
Interleukin 12 (IL-12) is a potent enhancer of
interferon T helper (Th)1 cells can
be categorized according to their cytokine expression profiles. The
differential generation of Th cells expressing Th1 and/or Th2 cytokines
is key to the outcome of both protective and pathologic immune
responses (1, 2). Th1 cells secrete high levels of IFN A functional high-affinity IL-12R is composed of two protein subunits,
the IL-12R To this aim, we cloned 0.6 kilobase of the 5' flanking region and, by
serial truncation, tested for promoter activity applying a reporter
gene assay in IL-12R Materials--
Restriction enzymes and T4 ligase were purchased
from Promega (Leiden, The Netherlands). All high pressure liquid
chromatography-purified oligonucleotides were purchased from
BIOSOURCE (Nivelles, Belgium). BstEII-digested Plasmid Construction--
Clone pAC188 containing
IL-12R Mutagenesis--
Site-directed mutagenesis of the IL-12R Transient Transfection Studies--
Jurkat cells (5 × 10)
(6) expressing both IL-12R T-cell Isolation, Culture, and
Stimulation--
Peripheral blood mononuclear cells from
healthy individuals were isolated by density gradient centrifugation on
Lymphoprep (Nycomed, Torshov, Norway). Highly purified CD4+
T cells (normally >98% as assessed by flow cytometry) were obtained from peripheral blood mononuclear cells with anti-CD4-coated Dynabeads (Dynal AS, Oslo, Norway) as described before (12). CD45RA+
CD45RO Preparation of Whole Cell and Nuclear Protein Extracts and
Electrophoretic Mobility Shift Assays--
Whole cell protein extracts
were prepared from 5 × 106 CD4+ T cells.
Nuclear protein extracts were prepared from 5 × 106
cells CD4+, Th1, or Th2 cells, which were left unstimulated
or were stimulated with anti-CD3/anti-CD28 for 30 min in the presence
or absence of cyclosporin A (CsA; 1 µg/ml, Sigma-Aldrich). Cells were
washed with ice-cold phosphate-buffered saline. Nuclear and whole cell protein extracts were isolated essentially as described before (8), and
the protein concentrations were determined by a Bradford microassay
(Bio-Rad) using a calibrated solution of bovine serum albumin
(Sigma-Aldrich) as a reference. The samples were aliquoted and stored
at Reverse Transcriptase (RT)-PCR and Real-time Quantitative RT-PCR
Analysis of IL-12R Identification of the IL-12R Identification of Functional Motifs in the Core Promoter and
Negative Regulatory Region--
Two potential binding sites for the
SP-1 family of transcription factors (core sequence GGGCGG (16)) are
located in the proximal promoter region at Identification of Nuclear Factors Binding to the Identification of Nuclear Factors Binding to the
Because expression of the IL-12R IL-12R In this report, we have described the first data on the
transcriptional regulation of the human IL-12R The core promoter, which drives TCR-induced transcription (construct
We show here that IL-12R Similar negative regulatory effects of NFATc2 have been
implicated in the regulation of several Th2 type cytokine genes in the
mouse (21, 22). Indirect data on the regulation of the human
IL-13 gene points in the same direction (24). The present data are the first to suggest a suppressor function of NFATc2 in the
regulation of a gene associated with Th1-type responses. Whether or not
this site contributes to the polarization process of Th cells under Th1
or Th2 driving conditions is unclear thus far, as sites directly
involved in the Th2-specific suppression of the IL-12R It is to be expected that several Th1- or Th2-specific transcription
factors do play a role in IL-12R We thank Ing. J. Wormmeester for technical
support and Drs. J. L. M. Schoneveld (Academic Medical Center,
Dept. of Anatomy and Embryology, Amsterdam) and Dr. M. F. A.
Bierhuizen (University Medical Center Utrecht, Dept. of Medical
Physiology, Utrecht, the Netherlands) for helpful discussions.
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF349574.
¶
Supported by Grant 96.45 from the Netherlands Asthma Foundation.
**
To whom correspondence should be addressed: Academic Medical
Center, University of Amsterdam, Dept. of Cell Biology and Histology, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands. Tel.:
31-20-5664961; Fax: 31-20-6974156; E-mail:
E.A.Wierenga@amc.uva.nl.
Published, JBC Papers in Press, July 3, 2001, DOI 10.1074/jbc.M102536200
The abbreviations used are:
Th, T helper;
IFN
Silencer Activity of NFATc2 in the Interleukin-12 Receptor
2
Proximal Promoter in Human T Helper Cells*
§,
¶,
,
,
,
**
Academic Medical Center, University of
Amsterdam, Department of Cell Biology and Histology, P. O. Box
22700, 1100 DE Amsterdam, § Tanox Pharma B.V., Kruislaan
318, 1098 SM Amsterdam, and
Free University Medical
Center, Department of Molecular Cell Biology, P. O. Box 7057, 1007 MB
Amsterdam, The Netherlands
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
production by activated T cells. The high-affinity IL-12
receptor (IL-12R) is a heterodimer of a
1 and a
2 subunit.
Expression of the signaling IL-12R
2 chain is usually low, as
compared with the more abundant
1 chain, and may be rate-limiting
for IL-12 sensitivity. Little is known about the mechanisms controlling IL-12R
2 gene expression. Reporter
gene assays in IL-12R
2-expressing Jurkat cells showed that
truncation of the region from
151 to
61 abrogated promoter
activity. The proximal promoter region does not contain a typical TATA
box, suggesting a role for SP-1. Indeed, mutagenesis of the
63 SP-1
consensus site decreased transcription by 50%. Electrophoretic
mobility shift experiments confirmed the binding of SP-1 and
SP-3 at this site. In contrast, truncation of
252 to
192 increased
promoter activity. Likewise, mutagenesis of the consensus nuclear
factor of activated T cells site at
206 increased promoter
activity by 70%, suggesting silencer activity of this element.
Electrophoretic mobility shift experiments with primary Th (T helper)
cells showed the formation of a specific, T-cell receptor-inducible
complex at this site that is sensitive to cyclosporin A and
supershifted with anti-NFATc2 in both Th1 and Th2 cells. Accordingly,
cyclosporin A dose-dependently increased IL-12R
2
mRNA expression. These first data on
IL-12R
2 gene regulation indicate a TATA-less
promoter, depending on SP-1/SP-3 transcription factors, and a negative
regulatory NFAT element at
206. This element may contribute to the
overall low level of IL-12R
2 expression on Th cells.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
and favor
cellular immunity to intracellular pathogens, whereas Th2 cells secrete
IL-4 and favor humoral immunity to extracellular pathogens (3). The polarization process of naive T cells is directed by cytokines that are
present during initiation of the naive T-cell response. In this
respect, IL-4 promotes Th2 cell development, whereas the antigen-presenting cell-derived cytokine IL-12 is a potent inducer of
IFN
production and of the generation of Th1 cells (4, 5). For Th
cells to respond to these cytokines, they need functional receptors.
1 and IL-12R
2 chains. In the human the
1 and
2
subunits contribute equally to IL-12 binding (6). The
2 chain,
however, appears to be rate-limiting for IL-12 responsiveness, as it is
crucial for signal transduction (7) and, in contrast to the more
abundant
1 chain, is expressed to a maximum of only a few hundred
molecules per cell (6). We have previously shown that allergen-specific
Th2 cell clones generated from atopic patients revealed a complete lack
of signaling via the IL-12R, as indicated by their inability to
phosphorylate STAT4 (8) and to secrete IFN
in response to IL-12.
Rogge et al. (6) showed that development of naive T cells
into Th2 cells is associated with IL-4-mediated suppression of
IL-12R
2 mRNA and protein expression leading to the loss of IL-12
responsiveness and, consequently, the inability of IL-12 to promote
IFN
production (9). As IL-12 responsiveness is a major parameter in
the regulation of specific immunity, we started to unravel the
molecular mechanisms that govern the transcriptional regulation of the
IL-12R
2 gene in human Th cells.
2-expressing Jurkat T cells. In this report we
provide the first experimental evidence that SP-1 family members are
important for basal and inducible activity of the TATA-less core
promoter of the IL-12R
2 gene and that the inducible transcription factor NFATc2 binding at
206 has a
suppressive role in IL-12R
2 expression. This suppressive activity
does not underlie the loss of IL-12R
2 expression in Th2 cells.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
DNA (New England Biolabs, Beverly, MA)
was used as a molecular weight reference.
2-encoding genomic DNA was selected by screening a human
genomic pAC library (Genome Technology Center, Leiden University
Medical Center, Leiden, The Netherlands) using IL-12R
2
cDNA (+781 to +3229) as a probe. Starting from IL-12R
2 exon 1, clone pAC188 was sequenced in the 5' direction. A fragment spanning
591 to +54 (relative to the start of the reported cDNA sequence
(10)), designated construct
591, was amplified by PCR using
the pAC188 plasmid as a template. For cloning purposes, the 5'-sense
primers were designed with an additional SacI restriction
site and the 3'-antisense primer with a natural HincII site,
resulting in PCR products spanning through +54. Serial deletion
fragments, designated
404 (
404 to +54),
252 (
252 to +54),
192
(
192 to +54),
151 (
151 to +54),
61 (
61 to +54), and
36
(
36 to +54), were generated by varying the 5'-sense primer (Table I).
The PCR products were subcloned into the pGEM®-T Easy plasmid
(Promega) following the directions of the manufacturer. All constructs
were checked by DNA sequencing using Thermo Sequenase (PerkinElmer Life Sciences) on an ABI Prism 310 Genetic Analyzer (PerkinElmer Life Sciences). For transfection studies pGL3-enhancer (pGL3e) vector (Promega) was used, which contains the Firefly luciferase gene. The cloned PCR products and the pGL3e vector (Promega)
were digested with SacI and HincII or
SacI and SmaI, respectively, agarose gel-purified
(Qiagen, Hilden, Germany), and ligated with T4 DNA ligase (Promega).
pGL3e constructs were checked by sequencing. Plasmid DNA was prepared
from bacterial cultures using Qiagen Plasmid Midi Kits.
2
591 to +54 promoter construct was carried out using the Altered Sites
II in vitro mutagenesis system from Promega. All reactions
were carried out according to the manufacturer's instructions. The
internal forward primers containing the mutated sites are shown in
Table I. Products from this procedure were cloned into pGL3e and
sequenced to confirm the introduction of the desired mutations.
1 and IL-12R
2 were electroporated in
the presence of 20 µg of plasmid DNA in 0.5 ml of cytomix, as
described previously (11), in a 0.4-cm gap electroporation cuvette
(Bio-Rad) at 310 V, 900 microfarads using a Gene Pulser (Bio-Rad). To
monitor transfection efficiency, 250 ng of pRL-CMV, an expression
vector containing the Renilla luciferase gene under the
control of a cytomegalovirus promoter (Promega), was added to each
sample. To compensate for size differences of the constructs, empty
pGL3e vector was added to obtain an equal amount of DNA in each sample.
Immediately after transfection, 9.5 ml of complete culture medium was
added (Iscove's modified Dulbecco's medium, BioWhittaker,
Walkersville, MD) supplemented with 5% pooled, C-inactivated fetal
calf serum (BioWhittaker) and gentamycin (80 µg/ml; Duchafa, Haarlem,
The Netherlands). Cells were seeded in 2 wells of a 6-well culture
plate (Costar, Cambridge, MA). After 1 day of culture at 37 °C,
cells were either left unstimulated or stimulated for 24 h with 1 ng/ml PMA and 1 µg/ml ionomycin (Sigma-Aldrich) or with mouse mAbs to
CD3 (1 µg/ml; CLB-T3/4E) and CD28 (2 µg/ml; CLB-CD28/1), both
obtained from the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (CLB, Amsterdam, The Netherlands). Cells were harvested 48 h post-transfection. Using the Dual Luciferase
reporter gene assay (Promega), cell lysates were prepared and both
Firefly luciferase and Renilla luciferase were measured by a
dual luminometer (Promega). Luciferase activities were normalized for
transfection efficiency using Renilla luciferase activity.
Transfections were performed in duplicate, and the results of at least
three independent experiments were calculated as the mean ± S.D.
values for luciferase activity.
naive Th cells were isolated from peripheral blood
mononuclear cells through one-step high-affinity negative selection
columns (R&D Systems, Abingdon, UK). Naive Th cells were stimulated
under Th1 or Th2 driving conditions in IL-12 and IL-4, respectively, as
described before (13) to generate highly polarized Th1 and Th2 cells.
To test the effect of CsA on IL-12R
2 mRNA expression, naive Th
cells were stimulated for 3 days with immobilized CD3 mAb and soluble
CD28 mAb (13) in 96-well culture plates (Costar; 10 (5) cells/well)
with or without CsA at increasing concentrations (10-1000 ng/ml). All
T-cell cultures were grown in complete culture medium with rIL-2 (10 units/ml; Chiron, Emeryville, CA). Proliferative responses were assayed
in parallel cultures of 2 × 10 (4) cells/well after 3 days as
described before (12).
80 °C. An electrophoretic mobility shift assay (EMSA) was
performed as described before (8) with some minor modifications. The
double-stranded DNA probe was [
-32P]dATP-labeled using
the Prime-a-gene labeling system (Promega) and purified using Bio-Spin
6 chromatography columns (Bio-Rad). The binding reaction was incubated
at 4 °C for 45 min. Cold competitor oligonucleotides were added to
the reaction mix prior to the protein extract. The SP-1 consensus
sequence, binding SP-1 family members, is derived from human
herpesvirus. The NF-
B consensus oligonucleotide was obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). The nomenclature and
sequences of the oligonucleotides used in this study are summarized in
Table I. For supershift experiments, 4 µg of IgG1 mAb
NFATc1 (sc-7294, Santa Cruz), 0.5 µg of IgG1 mAb NFATc2
(BD Transduction Laboratories, San Diego, CA), 0.4 µg of polyclonal
IgG SP-1 antibody (sc-59-G, Santa Cruz), 4 µg of IgG1 mAb
SP-3 (sc-644-G, Santa Cruz), or a nonrelevant IgG1 isotype
control were added to the binding reaction for an additional 45 min at
4 °C. The whole sample was then loaded onto a 4% polyacrylamide gel
in 0.5× Tris/borate/EDTA buffer. The gels were prerun for 30 min and then run for 2 h at RT at 150 V. The gels were transferred to Whatman filter paper, dried, and exposed to x-ray film (Kodak XAR5
films, Rochester, NY) at
80 °C.
1, IL-12R
2, IL-2, and
2m mRNA Expression
and IL-13 Measurement--
RT-PCR was performed as described before
(14) with IL-12R
1-, IL-12R
2-, and
2-microglobulin
(
2m)-specific primers (Table I). For quantitative analysis of
IL-12R
2 mRNA expression, naive Th cells were stimulated as
described above and lysed for total RNA extraction at day 3 using a
Nucleo Spin RNA isolation kit (Macherey-Nagel, Duren, Germany).
First-strand cDNA was synthesized from total RNA using a cDNA
synthesis kit (MBI-Fermentas, St. Leon-Rot, Germany). Real-time
quantitative PCR was performed in a Light-Cycler (Roche Diagnostics,
Almere, The Netherlands) based on specific primers and general
fluorescence detection with SYBR green.
2m was used as a control.
The primer sequences for IL-12R
2 (melting temperature
60 °C), IL-2 (melting temperature 58 °C) and
2m (melting
temperature 60 °C) are listed in Table
I. Measurement of IL-13 levels in culture
supernatants were performed using the PeliKine compact human IL-13
enzyme-linked immunosorbent assay kit obtained from the CLB.
Oligonucleotides used in this study
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
2 Core Promoter and
Regulatory Regions--
To characterize the proximal promoter of the
human IL-12R
2 gene, we analyzed 0.6 kilobase of 5'
flanking sequence obtained from a genomic pAC clone. This fragment,
which is depicted in Fig. 1A,
spans the region
591 through +54 relative to the start of the
IL-12R
2 cDNA (10). In the immediate 5' region, no typical TATA
box or CCAAT box motif was found. To identify the core
promoter and regulatory elements, the transcriptional activity of the
truncated constructs of the IL-12R
2 5' upstream region (Fig.
2A) were assayed. For that
purpose, full-length construct
591 and a series of 5' deletion
fragments were subcloned into the pGL3-Enhancer vector, a promoterless
luciferase reporter vector with an SV40 enhancer. All constructs were
tested for promoter activity in unstimulated and
PMA/ionomycin-stimulated conditions in Jurkat T cells, showing constitutive expression of the IL-12R
1 chain and low but inducible expression of the IL-12R
2 chain (Fig. 2B). The expression
of the IL-12R
2 chain in Jurkat cells has been described (15). Promoter activity was up-regulated in stimulated cells transfected with
constructs
591,
404,
252,
192, and
151. Deletion from
591
to
404 and further to
252 reduced the reporter activity stepwise,
suggesting multiple positive cis-acting elements between
591 and
252. Interestingly, deletion from
252 to
192 led to an
increase in promoter activity, suggesting the presence of a suppressor
element(s) in this region. Promoter activity was abrogated after
truncation to
61 and
36, indicating that sequences in close
upstream proximity of
61 are crucial for basal and inducible IL-12R
2 promoter activity. Similar results were found upon
stimulation with anti-CD3 and anti-CD28 (data not shown).

View larger version (31K):
[in a new window]
Fig. 1.
5' flanking genomic DNA
sequence. A, the region from
591 base pairs of the
human IL-12R
2 promoter through position +54 in exon 1 (14) was
tested for promoter activity. Numbering of the sequence is relative to
the start of the reported cDNA sequence (10), and the gene is
located on chromosome 1 at region p31.2 (33). B, sequence of
the 5' flanking genomic DNA sequence as deposited under
GenBankTM accession number AF349574. The most distal 5'
nucleotide of each oligonucleotide used to construct the different
deletion fragments is indicated by a gray triangle and is
named after this position accordingly. The most 3' +54 nucleotide of
all constructs is indicated by the black triangle. SP-1
family consensus binding elements (SP-1#1 and SP-1#2) and the NFAT
consensus binding element are indicated in bold type above
the consensus sequence (underlined).

View larger version (33K):
[in a new window]
Fig. 2.
Reporter gene analysis of the
IL-12R
2 proximal promoter. A,
the 5'deletion fragments of the IL-12R
2 promoter, as described under
"Experimental Procedures," were linked to the Firefly luciferase
reporter gene (Luc). The fusion constructs were transiently
transfected into Jurkat cells. One day after transfection, cells were
either or not stimulated with PMA/ionomycin for 24 h.
Luciferase activity values are corrected for transfection efficiency
(Renilla luciferase) and DNA amount (empty vector was added
to compensate for size differences between constructs), and are
expressed as relative luciferase activity units, shown in this
and subsequent figures as the mean ± S.D. of at least three
independent duplicate experiments. In addition to deletion fragments,
pGL3e (empty vector) is shown as a control. B, RT-PCR
analysis of IL-12R
1, IL-12R
2, and
2m mRNA expression in
Jurkat T cells. Cells were cultured in the absence (lane 1)
or presence (lane 2) of PMA/ionomycin for 16 h.
Lane 3 represents the negative control containing no
template in the RT-PCR reaction. Fragment sizes in the 100-base pair
marker (M) are indicated in kilobase pairs
(kbp).
3 and
63 (Fig.
1B). As SP-1 is frequently involved in transcription
initiation in the absence of a TATA box (16), we analyzed whether these
DNA motifs at
3 (SP-1#1) and
63 (SP-1#2) participate in the
regulation of IL-12R
2 promoter activity. To examine the relative
roles of these two SP-1 sites for promoter activity, we mutated the
GGGCGG motifs in these elements to GTTCGG in the
context of the full-length promoter construct
591. We thus generated
two IL-12R
2 -591 to +54 promoter-reporter gene constructs with
either one of the SP-1 sites mutated. Promoter activity was tested
after transient transfection of Jurkat cells and compared with the wild
type full-length IL-12R
2 promoter activity. As shown in Fig.
3, mutation of the SP-1#1 site at
3 does not result in a significant change of activity, whereas mutation of the SP-1#2 site at
63 results in a reduction of promoter activity by almost 50%, suggesting an important role of this
cis-regulatory element. As determined by serial truncation,
deletion of the promoter region from
252 to
192 resulted in
increased promoter activity. Within this region a reversed NFAT
consensus binding site (TTTCC) is located at
206. To examine the
functional significance of this NFAT consensus site, we mutated the
TTTCC motif into TTTAA in the context of the full-length
promoter construct
591. Promoter activity was tested after transient
transfection of Jurkat cells and compared with the wild type construct
591. As shown in Fig. 3, a 70% increase of promoter activity was
observed with the mutated construct, suggesting that the putative NFAT
binding element at
206 has a negative cis-regulatory role
in IL-12R
2 transcription.

View larger version (17K):
[in a new window]
Fig. 3.
The
63 SP-1 and
206 NFAT motifs are
important for promoter activity. Jurkat cells were transiently
transfected with luciferase constructs containing the full-length wild
type promoter (construct
591) or the full-length promoter containing
the mutated SP-1 motifs at
3 or
63 (GGGCGG to GTTCGG),
or the mutated NFAT motif at
206 (TTTCC to TTTAA) as
indicated by stars. Cells were stimulated with PMA and
ionomycin for 24 h. Corrected luciferase activity was calculated,
and promoter activity was expressed as the percentage of wild type
promoter activity (top bar, 100%). In addition to deletion
fragments, pGL3e (empty vector) is shown as a control.
63 SP-1
Motif--
To characterize transcription factor binding activities at
the SP-1#2 element at
63, we performed EMSAs using whole cell extracts from CD4+ T cells. EMSA with the double-stranded
oligonucleotide SP-1#2 WT containing the intact
63 SP-1 element
demonstrated the formation of two DNA-protein complexes C1 and C2 (Fig.
4, lane 1) not formed in the
absence of protein extract (data not shown). The formation of these
radioactive complexes was dose-dependently inhibited by
competition with a 10-, 30-, or 90-fold molar excess of unlabeled SP-1#2 WT oligonucleotide (lanes 2-4) but was not affected
by a 90-fold molar excess of the mutated SP-1#2 Mut oligonucleotide (lane 5). Similar to the SP-1#2 WT oligonucleotide,
competition with a 10-, 30-, and 90-fold molar excess of a specific
SP-1 consensus oligonucleotide dose-dependently competed
the bands away (lane 6-8), whereas a 90-fold molar excess
of an oligonucleotide containing a nonrelevant NF-
B consensus
binding site had no effect (lane 9). SP-1 and SP-3 are known
to bind to identical DNA elements (17). Therefore, binding reactions
were performed in the presence of anti-SP-1, anti-SP-3, or both
antibodies. The addition of anti-SP-1 antibody resulted in a supershift
of most of complex C1 (Fig. 4, lane 11), whereas with
anti-SP-3 antibody, a complete supershift was observed of the less
abundant complex C2 (lane 12). The combination of both
anti-SP-1 and anti-SP-3 antibodies did not result in additional shifts.
These results suggest the binding of SP-1 and SP-3 at the
63
element.

View larger version (67K):
[in a new window]
Fig. 4.
Identification of
63 binding proteins.
The SP-1#2 wild type (WT) radiolabeled probe was incubated
with whole cell extracts from unstimulated CD4+ T cells.
The binding activities were competed for with excess cold
oligonucleotides: either SP-1#2 WT, SP-1#2 Mut, SP-1 herpesvirus
consensus, or nonrelevant NF-
B consensus. The -fold molar excess of
the competitor oligonucleotides is indicated, ranging from 10- to
90-fold. Arrowheads indicate specifically competed complexes
(C1 and C2). The addition of anti-SP-1
(lane 11), anti-SP-3 (lane 12), or both
(lane 13) resulted in the supershift (S) of
complex C1, C2, or both, respectively.
206
NFAT Motif--
We next tested whether NFAT could actually interact
with the putative binding site at
206 in the IL-12R
2 promoter. To
this aim, we used the
220 to
180 DNA sequence as a double-stranded probe for EMSA. Nuclear extracts from anti-CD3/anti-CD28-stimulated CD4+ T cells showed the inducible formation of complex A in
addition to the increased intensity of a preexisting complex P (Fig.
5A, lanes 3 and
4). The formation of complexes A and P was abrogated by
mutation of the probe (TTTCC to TTTAA; data not shown).
Activation of the CD4+ T cells in the presence of the
immunosuppressant drug CsA, known to inhibit the nuclear
translocation of NFAT, inhibited the formation of complex A but not P
(Fig. 5B, lane 5). These results indeed suggest
the involvement of NFAT in complex formation with the
206 element. Of
the growing family of NFAT proteins, NFATc1 (NFATc, NFAT2) and NFATc2
(NFATp, NFAT1) are most prominent in peripheral T cells (18) and bind
to the same DNA motif (19, 20). To identify whether NFATc1 or NFATc2 is
involved in complex A, binding reactions were performed in the presence
of antibodies to NFATc1 or NFATc2. A supershifted band (S) was obtained
with NFATc2 antibody (Fig. 5A, lane 7) but not
with antibody to NFATc1 (Fig. 5A, lane 6) or with
the IgG1 isotype control antibody (data not shown), indicating the inducible binding of NFATc2 at
206.

View larger version (31K):
[in a new window]
Fig. 5.
Identification of
206-binding
proteins. The radiolabeled probe NFAT
206 wild type was
incubated with nuclear extracts from freshly isolated CD4+
T cells (A) or from polarized Th1 or Th2 cell lines
(B) that were left unstimulated or stimulated with
anti-CD3/anti-CD28 for 30 min. Specific complexes (P, A, and
S) are indicated by arrowheads. The binding
reactions were carried out in the absence or presence of specific
antibody to NFATc1 or NFATc2 or in the presence of IgG1
isotype control antibody as indicated. A, nuclear extracts
from CD4+ T cells. Preexisting complex P showed increased
binding activity upon T-cell stimulation. Complex A was induced after
stimulation (lane 4) and was CsA-sensitive (lane
5). The addition of anti-NFATc2 but not anti-NFATc1 results in the
supershift (S) of complex A but not complex P. As a control
both antibodies are shown in the absence of nuclear extract
(lanes 1 and 2). B, nuclear extracts
from Th1 or Th2 cells showed no differences in the formation of complex
P or A after TCR stimulation (lanes 1, 2 and 5, 6). Anti-NFATc2, but not anti-NFATc1, supershifts complex A
equally well in Th1 and Th2 cells (lanes 3, 4 and 7, 8). The IgG1 Isotype control is shown in lane
9.
2 gene is
suppressed in Th2 cells and NFATc2 plays a role in the suppression of
Th2-type cytokines (21, 22), we next tested for differential binding activity of NFATc2 to the
206 element comparing nuclear extracts from
Th1 and Th2 cells. However, neither in unstimulated nor in anti-CD3/anti-CD28 stimulated cells any difference was observed between
Th1 and Th2 cell extracts (Fig. 5B). Preexisting complex P
showed a similar increased intensity in Th1 and Th2 cells after TCR
stimulation. Also, complex A was induced to the same extent in
TCR-stimulated Th1 cells (lanes 1 and 2) and Th2
cells (lanes 5 and 6). Both in Th1 and Th2
extracts, complex A was supershifted with anti-NFATc2 (lanes
4 and 5 and 7 and 8). The isotype
control is shown in lane 9.
2 mRNA Expression Is Up-regulated by
CsA--
The data so far suggested a general suppressive role of
NFATc2 in the regulation of IL-12R
2 expression, not discriminating between Th1 and Th2 cells. To test the role of NFAT in a more physiological system, naive T cells were stimulated for 3 days with anti-CD3/anti-CD28 in the presence of increasing concentrations of
CsA. The mRNA expression of IL-12R
2, IL-2, and
2m was
measured by real-time PCR. The levels of IL-12R
2 and IL-2 mRNA
were normalized based on
2m mRNA levels in the same samples.
Both IL-2 mRNA expression level, known to be inhibited by CsA (23),
and IL-13 protein secretion, known to be enhanced by CsA (24), were
used as controls. As expected from the EMSA data, CsA
dose-dependently increased IL-12R
2 mRNA expression
(Fig. 6A), confirming the
suppressive role of NFAT herein. Furthermore, the IL-2 mRNA
expression was decreased (Fig. 6A), and the IL-13 protein
secretion was increased (Fig. 6B) in the presence of
increasing doses of CsA.

View larger version (15K):
[in a new window]
Fig. 6.
CsA increases
IL-12R
2 mRNA expression. Naive T
cells were stimulated with anti-CD3/anti-CD28 in the absence or
presence of increasing concentrations of CsA. After 3 days, cells were
lysed and IL-12R
2, IL-2, and
2m mRNA expression were analyzed
by real-time PCR. IL-13 protein expression was measured by
enzyme-linked immunosorbent assay in the supernatant. A, the
levels of IL-12R
2 (filled triangles) and IL-2 (open
circles) mRNA expression were normalized based on the level of
2m mRNA expression in the same samples and calculated as
arbitrary units/
2m. The IL-12R
2/
2m and IL-2/
2m mRNA
ratios are expressed as the percentage of the ratio in the absence of
CsA (100%). B, the IL-13 protein concentration in the
supernatant is expressed as the percentage of IL-13 protein secreted in
the absence of CsA (100%). This figure shows one representative
experiment of three.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
2 gene. The
proximal promoter region was cloned and functionally characterized. The data indicate a TATA-less promoter, dependent on SP-1 family protein binding at
63, and a silencer NFAT element at
206, which binds NFATc2 and is involved in suppressing TCR-induced IL-12R
2
expression. The pGL3e vector in which the promoter fragments were
cloned contains an SV-40 enhancer located upstream of the
luciferase gene. The enhancer element normally increases
reporter gene expression provided that the promoter is active. Deletion
from
151 to
61 resulted in fully abrogated transcription, even in
the presence of the enhancer, underlining the critical role of this
region in transcription initiation.
151), does not contain a TATA or CAAT box. In the absence of a TATA
box, SP-1 binding motifs are frequently involved in alternative
initiation of transcription (25, 26). This seems to apply for the
IL-12R
2 gene as well, as it contains a functional SP-1/3
binding motif in its core promoter. Genes with TATA-less promoters,
including many so-called "housekeeping" and receptor genes, are
generally expressed at low levels (27). Indeed, even fully
IL-12-responsive Th1 cells were shown to express only a few hundred
IL-12R
2 molecules on their membrane (6). The IL-12R
2 gene contains a GC-rich (±75%) 5' noncoding region (10), which may,
at least in part, explain the low rate of expression of these molecules, as GC-rich 5' noncoding regions are known to hamper translation (27). However, data on the translational regulation of the
IL-12R
2 mRNA are not available yet.
2 expression is inhibited at the
transcriptional level. The NFAT element at
206 specifically binds NFATc2 and seems to be important for a general down-regulation of
TCR-inducible IL-12R
2 gene expression. The availability
and suppressive activity of NFATc2 does not discriminate between Th1 and Th2 cells and thus does not explain the loss of expression of the
IL-12R
2 chain in Th2 cells. The relative importance of the negative
regulatory role of this element is underlined by the observation that
CsA increases IL-12R
2 mRNA expression in stimulated naive Th
cells, i.e. in the context of fully intact regulatory
regions, instead of the cloned proximal 591 base pairs of the promoter.
The absence of further NFAT sites in the region, at least up to
1.2
kilobases (data not shown), further indicates this particular site as
the mediator of the CsA-sensitive suppressive effect.
2
gene have not been identified yet. Our present data give no indication
for differential NFATc2 activity at
206 in Th1 and Th2 cells.
Instead, NFATc2 may play a role in the general low expression rate (6)
or the kinetics of IL-12R
2 gene expression, in particular
in the shut-down of expression at later time points after TCR
triggering as has been suggested in the regulation of IL-4
gene expression (28).
2 gene transcription either in a direct or an indirect way. For example, IL-12 strongly up-regulates IL-12R
2 expression through phosphorylation
of STAT4 (6). Therefore, STAT4 binding sites are expected to be located in the enhancer region further upstream as has been suggested before
(29). Another transcription factor which may be directly involved in
IL-12R
2 gene regulation is the recently identified, Th1-specific T-box transcription factor, T-bet (30). T-bet is up-regulated by IL-12 and accounts for the Th1-specific expression of
IFN
and repression of the opposing Th2 programs, at least in
the mouse. In contrast, GATA-3, a Th2-specific and IL-4-induced transcription factor (31), may be involved in the direct suppression of
the IL-12R
2 gene. Indeed, Ouyang et al. (32)
demonstrated a decrease in IL-12R
2 mRNA expression after ectopic
expression of GATA-3 into differentiated murine Th1 cells. We are
currently investigating the role of Th1- and Th2-specific transcription factors in human IL-12R
2 gene expression.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
![]()
ABBREVIATIONS
, interferon
;
IL, interleukin;
IL-12R, interleukin-12
receptor;
TCR, T-cell receptor;
STAT, signal transducers and activators
of transcription;
NFAT, nuclear factor of activated T cells;
PCR, polymerase chain reaction;
RT, room temperature;
PMA, phorbol
12-myristate 13-acetate;
mAb, monoclonal antibody;
CsA, cyclosporin A;
EMSA, electrophoretic mobility shift assay;
2m,
2-microglobulin;
CLB, Central Laboratory of the Netherlands Red Cross Blood Transfusion
Service.
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Salgame, P.,
Abrams, J. S.,
Clayberger, C.,
Goldstein, H.,
Convit, J.,
Modlin, R. L.,
and Bloom, B. R.
(1991)
Science
254,
279-282
2.
Romagnani, S.
(1991)
Immunol. Today
12,
256-257
3.
O'Garra, A.
(1998)
Immunity
8,
275-283
4.
Manetti, R.,
Gerosa, F.,
Giudizi, M. G.,
Biagiotti, R.,
Parronchi, P.,
Piccinni, M. P.,
Sampognaro, S.,
Maggi, E.,
Romagnani, S.,
and Trinchieri, G.
(1994)
J. Exp. Med.
179,
1273-1283
5.
Maggi, E.,
Parronchi, P.,
Manetti, R.,
Simonelli, C.,
Piccinni, M. P.,
Rugiu, F. S.,
De Carli, M.,
Ricci, M.,
and Sinigaglia, F.
(1992)
J. Immunol.
148,
2142-2147
6.
Rogge, L.,
Barberis-Maino, L.,
Biffi, M.,
Passini, N.,
Presky, D. H.,
Gubler, U.,
and Sinigaglia, F.
(1997)
J. Exp. Med.
185,
825-831
7.
Chua, A. O.,
Chizzonite, R.,
Desai, B. B.,
Truitt, T. P.,
Nunes, P.,
Minetti, L. J.,
Warrier, R. R.,
Presky, D. H.,
Levine, J. F.,
and Gately, M. K.
(1994)
J. Immunol.
153,
128-136
8.
Hilkens, C. M.,
Messer, G.,
Tesselaar, K.,
van Rietschoten, A. G.,
Kapsenberg, M. L.,
and Wierenga, E. A.
(1996)
J. Immunol.
157,
4316-4321
9.
Rogge, L.,
Papi, A.,
Presky, D. H.,
Biffi, M.,
Minetti, L. J.,
Miotto,
Agostini, C.,
Semenzato, G.,
Fabbri, L. M.,
and Sinigaglia, F.
(1999)
J. Immunol.
162,
3926-3932
10.
Presky, D. H.,
Yang, H.,
Minetti, L. J.,
Chua, A. O.,
Nabavi, N.,
Wu, C. Y.,
Gately, M. K.,
and Gubler, U.
(1996)
Proc. Natl. Acad. Scie. U. S. A.
93,
14002-14007
11.
van den Hoff, M. J. B.,
Christoffels, V. M.,
Labruyere, W. T.,
Moorman, A. F. M.,
and Lamers, W. H
(1995)
Meth. Mol. Biol.
48,
185-197
12.
Vieira, P. L.,
Kalinski, P.,
Wierenga, E. A.,
Kapsenberg, M. L.,
and de Jong, E. C.
(1998)
J. Immunol.
161,
5245-5251
13.
Smits, H. H.,
van Rietschoten, J. G. I.,
Hilkens, C. M.,
Sayilir, R.,
Stiekema, F. E.,
Kapsenberg, M. L.,
and Wierenga, E. A.
(2001)
Eur. J. Immunol.
31,
1055-1065
14.
van Rietschoten, J. G. I.,
Smits, H. H.,
Westland, R.,
Verweij, C. L.,
den Hartog, M. T.,
and Wierenga, E. A.
(2000)
Immunogenetics
51,
30-36
15.
Yokoe, T.,
Suzuki, N.,
Minoguchi, K.,
Adachi, M.,
and Sakane, T.
(2001)
Cell. Immunol.
208,
34-42
16.
Suske, P.
(1999)
Gene
238,
291-300
17.
Lania, L.,
Majello, B.,
and De Luca, P.
(1997)
Int. J. Bioch. Cell Biol.
29,
1313-1323
18.
Kuo, C. T.,
and Leiden, J. M.
(1999)
Ann. Rev. Immunol.
17,
149-187
19.
Hoey, T.,
Sun, Y. L.,
Williamson, K.,
and Xu, W.
(1995)
Immunity
2,
461-472
20.
Rao, A.,
Luo, C.,
and Hogan, P. G.
(1997)
Ann. Rev. Immunol.
15,
707-747
21.
Xanthoudakis, S.,
Viola, J. P. B.,
Shaw, K. T. Y.,
Luo, C.,
Wallace, L. D.,
Bozza, P. T.,
Curran, T.,
and Rao, A.
(1996)
Science
272,
892-895
22.
Hodge, M. R.,
Ranger, A. M.,
de la Brousse, F. C.,
Hoey, T.,
Grusby, M. J.,
and Glimcher, L. H.
(1996)
Immunity
4,
397-405
23.
Manger, B.,
Hardy, K. J.,
Weiss, A.,
and Stobo, J. D.
(1986)
J. Clin. Invest.
77,
1501-1506
24.
Van der Pouw Kraan, T. C.,
Kraan, T. C.,
Boeije, L. C.,
Troon, J. T.,
Rutschmann, S. K.,
Wijdenes,
and Aarden, L. A.
(1996)
J. Immunol.
156,
1818-1823
25.
Azizkhan, J. C.,
Jensen, D. E.,
Pierce, A. J.,
and Wade, M.
(1993)
Crit. Rev. Eukar. Gene Expr.
3,
229-254
26.
Dynan, W. S.,
and Tjian, R.
(1983)
Cell
35,
79-87
27.
Kozak, M.
(1991)
J. Cell Biol.
115,
887-903
28.
Ranger, A. M.,
Oukka, M.,
Rengarajan, J.,
and Glimcher, L. H.
(1998)
Immunity
9,
627-635
29.
Sinigaglia, F.,
D'Ambrosio, D.,
Panina-Bordignon, P.,
and Rogge, L.
(1999)
Immunol. Rev.
170,
65-72
30.
Szabo, S. J.,
Kim, S. T.,
Costa, G. L.,
Zhang, X.,
Fathman, C. G.,
and Glimcher, L. H.
(2000)
Cell
100,
655-669
31.
Zheng, W. P.,
and Flavell, R. A.
(1997)
Cell
89,
587-596
32.
Ouyang, W.,
Ranganath, S. H.,
Weindel, K.,
Bhattacharya, D.,
Murphy, T. L.,
Sha, W. C.,
and Murphy, K. M.
(1998)
Immunity
9,
745-755
33.
Yamamoto, K.,
Kobayashi, H.,
Miura, O.,
Hirosawa, S.,
and Miyasaka, N.
(1997)
Cytogenet. Cell Genet.
77,
257-258
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
M. Wittmann, C. Killig, M. Bruder, R. Gutzmer, and T. Werfel Critical involvement of IL-12 in IFN-{gamma} induction by calcineurin antagonists in activated human lymphocytes J. Leukoc. Biol., July 1, 2006; 80(1): 75 - 86. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Miyatake, H. Ikeda, A. Ishizu, T. Baba, T. Ichihashi, A. Suzuki, U. Tomaru, M. Kasahara, and T. Yoshiki Role of Neuronal Interferon-{gamma} in the Development of Myelopathy in Rats Infected with Human T-Cell Leukemia Virus Type 1 Am. J. Pathol., July 1, 2006; 169(1): 189 - 199. [Abstract] [Full Text] [PDF] |
||||
![]() |
H Ohyama, K Ogata, K Takeuchi, M Namisato, Y Fukutomi, F Nishimura, H Naruishi, T Ohira, K Hashimoto, T Liu, et al. Polymorphism of the 5' flanking region of the IL-12 receptor {beta}2 gene partially determines the clinical types of leprosy through impaired transcriptional activity J. Clin. Pathol., July 1, 2005; 58(7): 740 - 743. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. Badran, K. Kunstman, J. Stanton, M. Moschitta, A. Zerghe, H. Akl, A. Burny, S. M. Wolinsky, and K. E. Willard-Gallo Transcriptional Regulation of the Human CD3{gamma} Gene: The TATA-Less CD3{gamma} Promoter Functions via an Initiator and Contiguous Sp-Binding Elements J. Immunol., May 15, 2005; 174(10): 6238 - 6249. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||